Our Insights Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More Oncology Anthony Iannacci 7/1/26 Oncology Anthony Iannacci 7/1/26 TROP2 ADCs: A Major Innovation for 1L TNBC Read More Want to get in touch? Click here
Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More
Oncology Anthony Iannacci 7/1/26 Oncology Anthony Iannacci 7/1/26 TROP2 ADCs: A Major Innovation for 1L TNBC Read More
